‘Brain Monitoring Devices Market Worth Over $9 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report the Brain Monitoring Devices Market Forecast 2017-2027: Revenue Prospects by Device Type (Invasive & Non-Invasive), Product (EEG, CT, MRI, MEG, Others), Application (TBI, Epilepsy, Stroke, Others) and End-User (Hospitals, Neurological Centres, Other) indicates that the global brain monitoring devices market will see over $9bn in revenue in 2017.

The lead analyst of the report said:

“The brain monitoring devices market is expected to grow at a healthy CAGR over the study forecast period. The key drivers supporting the growth of the market are increasing prevalence and incidence neurological disorders such as epilepsy, stroke, and traumatic brain injuries. In addition, the increasing geriatric population, increasing awareness of brain function monitoring, and technological advancements in monitoring devices is further expected to fuel market growth. However, factors such as high cost of devices, lack of skilled labour force, and under penetration of diagnostics procedures in developing countries are likely to hinder the growth of the market in the near future.”
The 155-page report contains 119 tables, charts and graphs that add visual analysis in order to explain developing trends within the brain monitoring devices market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading brain monitoring devices submarkets, segmented by device type, with forecasts for invasive and non-invasive brain monitoring devices. The market is also segmented by product, and includes forecasts for Electroencephalogram (EEG), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetoencephalogram (MEG) and other brain monitoring devices. The report also includes forecasts for the applications of brain monitoring devices, including traumatic brain injuries (TBI), epilepsy, stroke and others. In addition, the report also contains forecasts for the brain monitoring devices market by end-user, including hospitals neurological centres and others.

The 155-page report offers market forecasts and analysis for 12 national markets, as well as the rest of the world, market. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the field in brain monitoring devices technology.

The Brain Monitoring Devices Market Forecast 2017-2027: Revenue Prospects by Device Type (Invasive & Non-Invasive), Product (EEG, CT, MRI, MEG, Others), Application (TBI, Epilepsy, Stroke, Others) and End-User (Hospitals, Neurological Centres, Other) report will be of value to anyone who wants to better understand the brain monitoring devices market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the brain monitoring devices industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read